Johnson & Johnson plans to test an experimental HIV vaccine in the U.S. and Europe, according to Bloomberg.
In the clinical trial set to begin later this year, about 3,800 men will receive a regimen of shots to test its efficacy.
If the vaccine is successful, it would be the first immunization against the deadly disease.
J&J is working to make a vaccine that will work in populations around the world that are infected with various strains of the virus. Other vaccines in late-stage studies have focused on preventing a single strain.
"The cost of treating HIV patients — the burden for patients, the burden for society — is very high," Paul Stoffels, J&J's chief scientific officer, told Bloomberg. HIV prevention is "a big mission for us. We've been working on it for almost 30 years."